Summary

On the call, Aaron discussed Bios’ concept of idea generation, what are some Long/Short ideas that might be of interest and why he thinks they are. Bios write a lot of short research. Aaron mentioned they were well ahead of the curve of these ridiculous preclinical billion dollar plus IPOs that were being done, even though they were being underwritten by fantastic investment firms, the valuations just made no sense. There's also been a significant amount of frauds, fads, and fakes that have been developed over the last two years with the help of COVID, etc. Aaron said that Bios has been on top of that and they’ve had a really great run on the short side. However, Aaron said that today he thinks some of the best opportunities are actually to go long. He thinks that it’s very similar to what energy was in the second half of 2020, no one wanted to touch it. It was almost like a curse word. Biotech is what must not be named right now in the investment world. Therefore, Aaron thinks there's a huge opportunity because of that. Aaron mentioned an example to give us an idea, looking at the XBI, which is a smaller cap, although not small cap, still most of these components are over a billion dollar in market cap. If you go under a billion dollars, that's where the real opportunities are. Aaron discussed Shorts such as: Inovio Pharmaceuticals, Inc. (INO), Ocugen (OCGN), CureVac (CVAC), Moderna (MRNA), etc. and Longs such as: Lorus Therapeutics, Inc. (APTO), REGENXBIO Inc. (RGNX), Eiger Biopharmaceuticals Inc. (EIGR), etc.

Topics